Τόμος 22 (2008) – Τεύχος 2 – Συμπλήρωμα 1 – Άρθρο 7 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Supplement 1 – Article 7 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Medical School, Demokritus University of Thrace, Alexandroupolis, Greece

2. Department of Hygiene and Epidemiology, Technological Educational Institution of Athens (TEI), Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Weber G.: Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture. Cancer Res. 43:  3466-3492 (1983)

3. Warburg O.: On the origin of cancer cells. Science 123: 309-314 (1956)

4. Weber G.: Enzymology of cancer cells (second part). N. Engl. J. Med. 296:  541-551 (1977)

5. Weber M.J., Nakamura K.D., Salter D.W.: Molecular events leading to enhanced glucose transport in rous sarcoma virus-transformed cells. Fed. Proc. 43: 2246-2250 (1984)

6. Flier J.S., Mueckler M.M., Usher P., et al.: Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235: 1492-1495 (1987)

7. Hiraki Y., Rosen O.M., Birnbaum M.J.: Growth factors rapidly induce expression of the glucose transporter gene. J. Biol. Chem. 263: 13655-13662 (1988)

8. Younes M., Brown R.W., Stephenson M., et al.: Overexpression of glut-1 and glut-3 in stage I non-small cell lung cancer is associated with poor survival. Cancer 80: 1046-1051 (1997)

9. Brown R.S., Wahl R.: Overexpression of glut-1 glucose transporter in human breast cancer: An immunohistochemical study. Cancer 72: 2979-2985 (1993)

10. Higashi T., Tamaki N., Honda T., et al.: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 38: 1337-1344 (1997)

11. Knox E.W., Jamdar S.C., Davis P.A.: Hexokinase, differentiation and growth rates of transplanted rat tumors. Cancer Res. 30: 2240-2244 (1970)

12. Weber G., Cantero A.: Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissues. Cancer Res. 15: 105-108 (1995)

13. Di Chiro G.: Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22: 360-371 (1987)

14. Gallagher B.M., Anasri A., Atkins M., et al.: Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardia] glucose metabolism in vivo: Tissue distribution and imaging studies in animals. J. Nucl. Med. 18: 990-996 (1997)

15. Monakhov N.K., Neistadt E.L., Shavlovski M.M., et al.: Physiochemical properties and isoenzyme composition of hexo-kinase from normal and malignant human tissues. J. Natl. Cancer Inst. 61: 27-34 (1978)

16. Gallagher B.M., Fowler J.S., Gutterson N.l., MacGregor R.R., Wan C.N., Wolf A.P.: Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J. Nucl. Med. 19: 1154-1161 (1978)

17. Som P., Atkins H.L., Bandoypadhyay D., et al.: A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J. Nucl. Med. 21: 670-675 (1980)

18. Zasadny K., Wahl R.L.: Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189: 847-850 (1993)

19. Di Chiro G., DeLaPaz R.L., Brooks R.A., et al.: Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxy-glucose and positron emission tomography. Neurology 32: 1323-1329 (1982)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr